Neoadjuvant chemoradiotherapy has a potential role in pancreatic carcinoma

Therapeutic Advances in Medical Oncology

Volumn 3, Issue 1, 2011, Pages 27-33

  Van Tienhoven, Geertjan ^a   Gouma, Dirk J ^a   Richel, Dick J ^a  

^a ACADEMIC MEDICAL CENTER   (Netherlands)

Author keywords

neoadjuvant; pancreatic cancer; radiochemotherapy

Indexed keywords

ANALGESIC AGENT; CAPECITABINE; CISPLATIN; CYCLOOXYGENASE 2 INHIBITOR; ERLOTINIB; FLUOROURACIL; FOLINIC ACID; GEMCITABINE; OXALIPLATIN;

ADD ON THERAPY; ADVANCED CANCER; CANCER ADJUVANT THERAPY; CANCER PAIN; CANCER RADIOTHERAPY; CANCER REGISTRY; CANCER SURGERY; CANCER SURVIVAL; COMPUTER ASSISTED TOMOGRAPHY; DRUG EFFICACY; HUMAN; LAPAROTOMY; MOLECULARLY TARGETED THERAPY; NUCLEAR MAGNETIC RESONANCE IMAGING; PANCREAS CARCINOMA; PHASE 2 CLINICAL TRIAL (TOPIC); PHASE 3 CLINICAL TRIAL (TOPIC); PRIORITY JOURNAL; PROGNOSIS; PROGRESSION FREE SURVIVAL; RADIATION DOSE; RANDOMIZED CONTROLLED TRIAL (TOPIC); REVIEW; SURGICAL TECHNIQUE;

EID: 79952831301     PISSN: 17588340     EISSN: 17588359     Source Type: Journal    
DOI: 10.1177/1758834010383150     Document Type: Review

References (44)

1. Azria D. Ychou M. Jacot W. Thezenas S. Lemanski C. Senesse P. et al (2002) Treatment of unresectable, locally advanced pancreatic adenocarcinoma with combined radiochemotherapy with 5-fluorouracil and cisplatin. Pancreas 25: 360–365.
2. Bernhard J. Dietrich D. Scheithauer W. Gerber D. Bodoky G. Ruhstaller T. ; Central European Cooperative Oncology Group. (2008) Clinical benefit and quality of life in patients with advanced pancreatic cancer receiving gemcitabine plus capecitabine versus gemcitabine alone: A randomized multicenter phase III clinical trial – SAKK 44/00-CECOG/PAN.1.3.001. J Clin Oncol 26: 3695–3701.
3. Brown K.M. Siripurapu V. Davidson M. Cohen S.J. Konski A. Watson J.C. et al (2008) Chemoradiation followed by chemotherapy before resection for borderline pancreatic adenocarcinoma. Am J Surg 195: 318–321.
4. Brunner T.B. Grabenbauer G.G. Meyer T. Golcher H. Sauer R. Hohenberger W. et al (2007) Primary resection versus neoadjuvant chemoradiation followed by resection for locally resectable or potentially resectable pancreatic carcinoma without distant metastasis. A multi-centre prospectively randomised phase II-study of the Interdisciplinary Working Group Gastrointestinal Tumours (AIO, ARO, and CAO). BMC Cancer 7: 41–42.
5. Ceha H.M. van Tienhoven G. Gouma D.J. Veenhof C.H. Schneider C.J. Rauws E.A. et al (2000) Feasibility and efficacy of high dose conformal radiotherapy for patients with locally advanced pancreatic carcinoma. Cancer 89: 2222–2229.
6. Chang D. Johns A. Merrett N. Gill A.J. Colvin E.K. Scarlett C.J. et al (2009) Margin clearance and outcome in resected pancreatic cancer. J Clin Oncol 27: 2855–2862.
7. Corsini M. Miller R. Haddock M. Donohue J.H. Farnell M.B. Nagorney D.M. et al (2008) Adjuvant radiotherapy and chemotherapy for pancreatic carcinoma / the Mayo Clinic experience (1975–2005). J Clin Oncol 26: 3511–3516.
8. Dutch Comprehensive Cancer Centres (2010) [homepage on the internet]. Netherlands Cancer Registry incidence data, Utrecht. Available at: www.kankerregistratie.nl (accessed 21 May 2010).
9. Evans D.B. Varadhachary G.R. Crane C.H. Sun C.C. Lee J.E. Pisters P.W. et al (2008) Preoperative gemcitabine-based chemoradiation for patients with resectable adenocarcinoma of the pancreatic head. J Clin Oncol 26: 3496–3502.
10. Gillen S. Schuster T. Meyer Zum Büschenfelde C. Friess H. Kleeff J. (2010) Preoperative / neoadjuvant therapy in pancreatic cancer: A systematic review and meta-analysis of response and resection percentages. PLoS Med 7: e1000267–e1000267.
11. Heinemann V. Quietzsch D. Gieseler F. Gonnermann M. Schönekäs H. Rost A. et al (2006) Randomized phase III trial of gemcitabine plus cisplatin compared with gemcitabine alone in advanced pancreatic cancer. J Clin Oncol 24: 3946–3952.
12. Herman J. Swartz M. Hsu C. Winter J. Pawlik T.M. Sugar E. et al (2008) Analysis of fluorouracil-based adjuvant chemotherapy and radiation after pancreaticoduodenectomy for ductal adenocarcinoma of the pancreas / results of a large, prospectively collected database at the John Hopkins Hospital. J Clin Oncol 26: 3503–3510.
13. Hidalgo M. (2010) Pancreatic cancer. N Engl J Med 362: 1605–1617.
14. Hsu C.C. Herman J.M. Corsini M.M. Winter J.M. Callister M.D. Haddock M.G. et al (2010) Adjuvant chemoradiation for pancreatic adenocarcinoma: The Johns Hopkins Hospital-Mayo Clinic collaborative study. Ann Surg Oncol 17: 981–990.
15. Huguet F. Girard N. Guerche C.S. Hennequin C. Mornex F. Azria D. (2009) Chemoradiotherapy in the management of locally advanced pancreatic carcinoma: A qualitative systematic review. J Clin Oncol 27: 2269–2277.
16. Jemal A. Siegel R. Ward E. Hao Y. Xu J. Thun M.J. (2009) Cancer statistics, 2009. CA Cancer J Clin 59: 225–249.
17. Jin H.L. Zhu H. Ling T.S. Zhang H.J. Shi R.H. (2009) Neoadjuvant chemoradiotherapy for resectable esophageal carcinoma: A meta-analysis. World J Gastroenterol 15: 5983–5991.
18. Kaiser M.H. Ellenberg S.S. (1985) Pancreatic cancer: Adjuvant combined radiation and chemotherapy following curative resection. Arch Surg 120: 899–903.
19. Klinkenbijl J.H. Jeekel J. Sahmoud T. van Pel R. Couvreur M.L. Veenhof C.H. et al (1999) Adjuvant radiotherapy and 5-fluorouracil after curative resection of cancer of the pancreas and periampullary region: Phase III trial of the EORTC gastrointestinal tract cancer cooperative group. Ann Surg 230: 776–782.
20. Le Scodan R. Mornex F. Girard N. Mercier C. Valette P.J. Ychou M. et al (2009) Preoperative chemoradiation in potentially resectable pancreatic adenocarcinoma: Feasibility, treatment effect evaluation and prognostic factors, analysis of the SFRO-FFCD9704 trial and literature review. Ann Oncol 20: 1387–1396.
21. Lind P.A. Isaksson B. Almström M. Johnsson A. Albiin N. Byström P. et al (2008) Efficacy of preoperative radiochemotherapy in patients with locally advanced pancreatic carcinoma. Acta Oncol 47: 413–420.
22. Moore M.J. Goldstein D. Hamm J. Figer A. Hecht J.R. Gallinger S. et al (2007) Erlotinib plus gemcitabine compared with gemcitabine alone in patients with advanced pancreatic cancer: A phase III trial of the National Cancer Institute of Canada Clinical Trials Group. J Clin Oncol 25: 1960–1966.
23. Morak M.M. Richel D.J. van Eijck C.H. Nuyttens M.M. van der Gaast A. Vervenne W.L. et al (2010) Phase II trial of uracil / tegafur plus leucovorin and celecoxib combined with radiotherapy in locally advanced pancreatic cancer. Radiother Oncol (Submitted).
24. Neoptolemos J. Büchler M. Stocken D.D. Ghaneh P. Smith D. Bassi C. et al (2005) ESPAC-3(v2): A multicenter, international, open-label, randomized, controlled phase III trial of adjuvant 5-fluorouracil/folinic acid (5-FU/FA) versus gemcitabine (GEM) in patients with resected pancreatic ductal adenocarcinoma. J Clin Oncol 27: 18s (suppl; abstr LBA4505).
25. Neoptolemos J.P. Stocken D.D. Dunn J.A. Almond J. Beger H.G. Pederzoli P. et al ; European Study Group for Pancreatic Cancer. (2001) Influence of resection margins on survival for patients with pancreatic cancer treated by adjuvant chemoradiation and / or chemotherapy in the ESPAC-1 randomized controlled trial. Ann Surg 234: 758–768.
26. Neoptolemos J. Stocken D.D. Friess H. Bassi C. Dunn J.A. Hickey H. et al (2004) European Study Group for Pancreatic Cancer. A randomized trial of chemoradiotherapy and chemotherapy after resection of pancreatic cancer. N Engl J Med 350: 1200–1210.
27. Oettle H. Post S. Neuhaus P. Gellert K. Langrehr J. Ridwelski K. et al (2007) Adjuvant chemotherapy with gemcitabine vs observation in patients undergoing curative-intent resection of pancreatic cancer: A randomized controlled trial. JAMA 297: 267–277.
28. Ohigashi H. Ishikawa O. Eguchi H. Takahashi H. Gotoh K. Yamada T. et al (2009) Feasibility and efficacy of combination therapy with preoperative full-dose gemcitabine, concurrent three-dimensional conformal radiation, surgery, and postoperative liver perfusion chemotherapy for T3-pancreatic cancer. Ann Surg 250: 88–95.
29. Phoa S.S. Reeders J.W. Stoker J. Rauws E.A. Gouma D.J. Laméris J.S. (2000) CT criteria for venous invasion in patients with pancreatic head carcinoma. Br J Radiol 73: 1159–1164.
30. Phoa S.S. Tilleman E.H. van Delden O.M. Bossuyt P.M. Gouma D.J. Laméris J.S. (2005) Value of CT criteria in predicting survival in patients with potentially resectable pancreatic head carcinoma. J Surg Oncol 91: 33–40.
31. Sasson A.R. Hoffman J.P. Ross E.A. Kagan S.A. Pingpank J.F. Eisenberg B.L. (2002) En bloc resection for locally advanced cancer of the pancreas: Is it worthwhile? J Gastrointest Surg 6: 147–157.
32. Satoi S. Yanagimoto H. Toyokawa H. Takahashi K. Matsui Y. Kitade H. et al (2009) Surgical results after preoperative chemoradiation therapy for patients with pancreatic cancer. Pancreas 38: 282–288.
33. Schnelldorfer T. Ware A.L. Sarr M.G. Smyrk T.C. Zhang L. Qin R. et al (2008) Long-term survival after pancreatoduodenectomy for pancreatic adenocarcinoma: Is cure possible? Ann Surg 247: 456–462.
34. Sener S.F. Fremgen A. Menck H.R. Winchester D.P. (1999) Pancreatic cancer: A report of treatment and survival trends for 100,313 patients diagnosed from 1985–1995, using the National Cancer database. J Am Coll Surg 189: 1–7–1–7.
35. Smeenk H.G. van Eijck C.H. Hop W.C. Erdmann J. Tran K.C. Debois M. et al (2007) Long-term survival and metastatic pattern of pancreatic and periampullary cancer after adjuvant chemoradiation or observation: Long-term results of EORTC trial 40891. Ann Surg 246: 734–740.
36. Stessin A.M. Meyer J.E. Sherr D.L. (2008) Neoadjuvant radiation is associated with improved survival in patients with resectable pancreatic cancer: An analysis of data from the surveillance, epidemiology, and end results (SEER) registry. Int J Radiat Oncol Biol Phys 72: 1128–1133.
37. Tinkl D. Grabenbauer G.G. Golcher H. Meyer T. Papadopoulos T. Hohenberger W. et al (2009) Downstaging of pancreatic carcinoma after neoadjuvant chemoradiation. Strahlenther Onkol 185: 557–566.
38. Turrini O. Viret F. Moureau-Zabotto L. Guiramand J. Moutardier V. Lelong B. et al (2009) Neoadjuvant 5 fluorouracil-cisplatin chemoradiation effect on survival in patients with resectable pancreatic head adenocarcinoma: A ten-year single institution experience. Oncology 76: 413–419.
39. van Geenen R.C. Keyzer-Dekker C.M. van Tienhoven G. Obertop H. Gouma D.J. (2002) Pain management of patients with unresectable peripancreatic carcinoma. World J Surg 26: 715–720.
40. van Laethem J.-L. Hammel P. Mornex F. Azria D. van Tienhoven G. Vergauwe P. et al (2010) Adjuvant gemcitabine alone versus gemcitabine-based chemoradiation after curative resection for pancreatic cancer: A randomized EORTC/FFCD/GERCOR phase II study. J Clin Oncol (submitted).
41. Varadhachary G.R. Wolff R.A. Crane C.H. Sun C.C. Lee J.E. Pisters P.W. et al (2008) Preoperative gemcitabine and cisplatin followed by gemcitabine-based chemoradiation for resectable adenocarcinoma of the pancreatic head. J Clin Oncol 26: 3487–3495.
42. Westgaard A. Larønningen S. Mellem C. Eide T.J. Clausen O.P. Møller B. et al (2009) Are survival predictions reliable? Hospital volume versus standardisation of histopathologic reporting for accuracy of survival estimates after pancreatoduodenectomy for adenocarcinoma. Eur J Cancer 45: 2850–2859.
43. Wong R.K. Tandan V. de Silva S. Figueredo A. (2007) Pre-operative radiotherapy and curative surgery for the management of localized rectal carcinoma. Cochrane Database Syst Rev : CD002102–CD002102.
44. Yip D. Karapetis C. Strickland A. Steer C.B. Goldstein D. (2006) Chemotherapy and radiotherapy for inoperable advanced pancreatic cancer. Cochrane Database Syst Rev 3: CD002093–CD002093.